$SPRC

Shrem Itschak sold $5K of SPRC

Shrem Itschak sold 462 shares of SciSparc Ltd. (SPRC) at $10.00 on 2026-06-01.

Original reporting
SEC EDGAR · Shrem Itschak
Published Jun 3, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SPRC
Neutral
medium confidence
Mentioned
$SPRC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SPRCNeutralLow
01

Why it matters

Traders may monitor for clustering of insider sales/buys or larger transactions, but this specific print is unlikely to drive a major repricing by itself.

02

Market read

A small insider sale disclosed today may slightly affect near-term sentiment, but it lacks a fundamental catalyst.

03

What to watch

No 10b5-1 plan is noted, but the filing alone doesn’t reveal intent, tax considerations, or whether other insiders are buying/selling around the same period.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-03) covering a sale on 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (director open-market sale).

Company-level read

Ticker impact

$SPRCNeutralMedium confidence
Context

SciSparc director Shrem Itschak sold 462 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is a routine insider transaction with modest proceeds ($4,620) and no stated fundamental catalyst; such prints typically have limited immediate market impact unless part of a larger pattern.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the small size.

Key entities

  • SciSparc Ltd.

    Subject of the SEC Form 4 insider transaction; director sold 462 shares at $10.00 on 2026-06-01.

  • Shrem Itschak

    Director who executed the open-market sale disclosed in the filing.

Related articles

$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

$SPRCMed

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

SciSparc Ltd. (Nasdaq: SPRC) said its subsidiary NeuroThera Labs (TSXV: NTLX) started a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a cannabinoid-based treatment for adult Tourette syndrome. The randomized, double-blind, placebo-controlled cross-over study follows Phase IIa results showing 21% average tic reduction.